摘要
Objective:To evaluate the clinical efficacy and safety of Xiaoxuming decoction(XXMD)in the treatment of stroke.Methods:Randomized controlled trials of XXMD in the treatment of stroke was searched from January 1,2015 to March 1,2020.The data extraction and methodological quality evaluation were carried out by two researchers according to the pre-established inclusion and exclusion criteria,and the final inclusion study was analyzed by meta using Revman5.3.Results:22 RCT literatures were included,with a total of 1947 cases.Compared with the control group,the experimental group could reduce the score of NIHSS scale(95%CI(-3.37,-2.19),P<0.001),stroke score(95%CI(-2.71,-1.85),P<0.001),and BI(95%CI(6.15,8.50,P<0.001).And the effective rate of the experimental group was 3.58 times higher than that of the control group,and the difference was statistically significant(95%CI(2.40,5.36),P=0.00001).Conclusion:XXMD combined with western medicine is superior to western medicine in improving the symptoms of neurological deficit and living ability and the effective rate of stroke.In terms of clinical effective rate,the effective rate of XXMD in acute stage is 1.02 times higher than that in non-acute stage.However,no improvement in efficiency was found after syndrome differentiation.Future research may achieve higher efficacy in syndrome types other than Fengtanyuzu.
